CANF Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

3.850

Open

3.690

VWAP

3.58

Vol

197.12K

Mkt Cap

7.46M

Low

3.410

Amount

705.69K

EV/EBITDA(TTM)

--

Total Shares

2.14M

EV

3.03M

EV/OCF(TTM)

--

P/S(TTM)

8.91

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Show More

Events Timeline

(ET)

2026-07-06

07:30:00

Can-Fite BioPharma Completes Enrollment of 247 Patients

2026-07-01 (ET)

2026-07-01

07:30:00

Can-Fite BioPharma's Namodenoson Phase 2a Study Shows Prolonged Survival

2026-03-30 (ET)

2026-03-30

07:40:00

Can-Fite Signs Licensing Agreement with Vetbiolix, Projected Revenue of $325M

2026-03-17 (ET)

2026-03-17

08:00:00

Can-Fite Secures Patent for Namodenoson-Based Weight Loss Drug

2026-03-04 (ET)

2026-03-04

07:10:00

Can-Fite BioPharma Announces Phase IIa Results for Namodenoson

News

Yahoo Finance

07-06Yahoo Finance

PinnedCan-Fite BioPharma Completes Enrollment of 247 Patients in Phase 3 Study

Newsfilter

07-06Newsfilter

Can-Fite BioPharma Completes Patient Enrollment for Psoriasis Clinical Trial

seekingalpha

07-02seekingalpha

Stock Futures Dip Ahead of Independence Day as Investors Remain Cautious

NASDAQ.COM

07-02NASDAQ.COM

Biotech Companies See Significant Stock Gains

stocktwits

07-01stocktwits

Can-Fite BioPharma Reports Positive Results in Pancreatic Cancer Study

NASDAQ.COM

07-01NASDAQ.COM

Can-Fite BioPharma's Phase 2a Study Shows Promising Results

Valuation Metrics

The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is 6.32, compared to its 5-year average forward P/E of -0.22. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-0.22

Current PE

6.32

Overvalued PE

4.84

Undervalued PE

-5.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.12

Current EV/EBITDA

-0.05

Overvalued EV/EBITDA

0.58

Undervalued EV/EBITDA

-0.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

21.71

Current PS

3.14

Overvalued PS

65.56

Undervalued PS

-22.14

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 329 candidates

Region: USRelative Vol: >= 1.50Moving Average Relationship: PriceAboveMA200, PriceCrossAboveMA20Support Resistance Relationship: PriceAroundResistance, PriceBreakUpperBollMacd: bullish, positive

Ticker

Name

Market Cap$

Can Fite Biopharma Ltd

6.36M

Where Food Comes From Inc

65.56M

SeaStar Medical Holding Corp

14.67M

Dlocal Ltd.

3.82B

Progress Software Corp

1.41B

Franklin Covey Co

276.51M

what stocks have have hit pivot bottom

Intellectia · 247 candidates

Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000

Ticker

Name

Market Cap$

Lifecore Biomedical Inc

149.91M

NovaGold Resources Inc

3.54B

GoldMining Inc

243.68M

Clearpoint Neuro Inc

282.10M

Paramount Gold Nevada Corp

137.45M

Can Fite Biopharma Ltd

6.59M

Whales Holding CANF

Trading Trends

People Also Watch

Frequently Asked Questions

What is Can Fite Biopharma Ltd (CANF) stock price today?

The current price of CANF is 3.48 USD — it has decreased -8.42

What is Can Fite Biopharma Ltd (CANF)'s business?

Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

What is the price predicton of CANF Stock?

Wall Street analysts forecast CANF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CANF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

Can Fite Biopharma Ltd revenue for the last quarter amounts to 155.00K USD, decreased -21.32

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

Can Fite Biopharma Ltd. EPS for the last quarter amounts to -3.33 USD, decreased -70.00

How many employees does Can Fite Biopharma Ltd (CANF). have?

Can Fite Biopharma Ltd (CANF) has 5 emplpoyees as of July 08 2026.

What is Can Fite Biopharma Ltd (CANF) market cap?

Today CANF has the market capitalization of 7.46M USD.